Sangamo Therapeutics, Inc. (SGMO)
| Market Cap | 134.80M |
| Revenue (ttm) | 18.76M |
| Net Income (ttm) | -328.05M |
| Shares Out | 207.51M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,934,316 |
| Open | 0.630 |
| Previous Close | 0.609 |
| Day's Range | 0.600 - 0.700 |
| 52-Week Range | 0.290 - 1.670 |
| Beta | 1.40 |
| Analysts | Buy |
| Price Target | 5.17 (+695.87%) |
| Earnings Date | May 9, 2024 |
About SGMO
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm... [Read more]
Financial Performance
In 2023, SGMO's revenue was $176.23 million, an increase of 58.34% compared to the previous year's $111.30 million. Losses were -$257.83 million, 34.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $5.17, which is an increase of 695.87% from the latest price.
News
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS.
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing.
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast.
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT.
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES PRICING OF $24.0 MILLION REGISTERED DIRECT OFFERING.
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results.
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION & BRAIN TRANSDUCTION.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA ALIGNMENT ON ABBREVIATED PATHWAY TO POTENTIAL APPROVAL AND EMA PRIME ELIGIBILITY FOR ST-920 IN FABRY DISEASE.
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY DISEASE SHOWING SUSTAINED BENEFIT AND DIFFERENTIATED SAFETY PROFILE.
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS.
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast.
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit.
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS.
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES SECOND QUARTER 2023 CONFERENCE CALL AND WEBCAST.
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
BRISBANE, Calif. & BOSTON--(BUSINESS WIRE)--SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING.
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Thera...
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
BRISBANE, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties ...
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ISARALGAGENE CIVAPARVOVEC FOR THE TREATMENT OF FABRY DISEASE.
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF LISA ROJKJAER, M.D., AS CHIEF MEDICAL OFFICER.
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT PRE-CLINICAL DATA FROM ITS GENOMIC ENGINEERING PLATFORM AT ASGCT.
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS.
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial resu...